Market Alert: Tyson Earnings Beat Estimates, Blackstone & Lilly Ink Multi-Billion Dollar Deals

This update was written automatically with AI from market data and news wire reports, and published without review by a person.

Key Takeaways

  • Tyson Foods (TSN) reported Q4 adjusted EPS of $0.61, beating the $0.53 estimate, though it issued a cautious sales outlook for fiscal 2027.
  • Blackstone Digital Infrastructure Trust (BXDC) entered a $5 billion deal to acquire a 75.1% stake in two Amazon (AMZN) data center campuses.
  • Eli Lilly (LLY) expanded its oncology and hematology pipeline by acquiring Calytrix Bio for up to $1.5 billion in cash.
  • Ukraine launched one of its largest drone attacks of the war, reportedly striking the Ilsky Oil Refinery and other industrial targets across Russia.

Tyson Foods Beats Q4 Estimates Amid Mixed 2027 Outlook

Tyson Foods (TSN) delivered a fourth-quarter earnings beat on Monday, posting adjusted EPS of $0.61 against analyst expectations of $0.53. Total sales reached $14.59 billion, slightly ahead of the $14.32 billion consensus. Despite the quarterly beat, the company reported a loss per share of $0.22, a sharp reversal from the $0.13 EPS recorded in the same period last year.

Looking ahead, Tyson provided a conservative forecast for fiscal 2027, projecting a sales decline of 3.5% to 5.5%. The company anticipates adjusted operating income between $1.7 billion and $2.15 B for the coming year. Additionally, capital expenditure is expected to rise to between $1.1 billion and $1.4 billion, surpassing the $965.2 million analysts had modeled.

Blackstone and Amazon Partner in $5 Billion Data Center Deal

Blackstone Digital Infrastructure Trust (BXDC) announced its inaugural investment through a massive $5 billion joint venture with Amazon Web Services (AWS). Under the agreement, Blackstone will acquire a 75.1% majority interest in two data center campuses located in Indiana and Mississippi.

The portfolio consists of 13 newly constructed data centers with an aggregate capacity of 647 megawatts. Amazon (AMZN) will retain a 24.9% stake and has signed long-term, triple-net leases for the facilities. Blackstone expects to fund its portion of the deal using $1.9 billion in cash from its recent IPO and $2.5 billion in new mortgage loans.

Eli Lilly Acquires Calytrix Bio for $1.5 Billion

Eli Lilly (LLY) has reached a definitive agreement to acquire Calytrix Bio for a total consideration of up to $1.5 billion in cash. The deal includes an upfront payment and subsequent milestone-based payouts. Calytrix is a biotechnology firm specializing in therapies for myeloproliferative neoplasms (MPNs), a group of rare blood cancers.

The acquisition centers on Calytrix’s lead asset, a biparatopic antibody targeting mutant calreticulin (mCALR). This driver mutation is a primary cause of essential thrombocythemia and myelofibrosis. The move underscores Lilly’s continued aggressive expansion into specialized oncology and hematology markets.

Energy and Industrial Sector Updates: M&A and Geopolitics

In the energy sector, Diamondback Energy (FANG) announced a deal to acquire Double Eagle units for $2.15 billion in cash and 15.56 million shares. The acquisition is expected to further consolidate Diamondback’s footprint in the Permian Basin, enhancing its drilling inventory and production scale.

Separately, Medline (MDLN) shareholders, including affiliates of Blackstone (BX) and Carlyle (CG), filed to offer 60 million shares of Class A common stock. Medline will not receive proceeds from the secondary offering but has agreed to repurchase $200 million of its own stock concurrently.

On the geopolitical front, Ukrainian forces reportedly struck Russia's Ilsky Oil Refinery as part of a massive drone barrage involving over 1,300 aircraft. The attack targeted critical energy infrastructure in the Krasnodar and Rostov regions. Market participants are closely monitoring these developments for potential impacts on global energy supplies and refined product pricing.

Disclaimer: This article is for informational purposes only and does not constitute financial advice. We are not financial professionals. The authors and/or site operators may hold positions in the companies or assets mentioned. Always do your own research before making financial decisions.
Scroll to Top